HOUSE-BILL 9040: H.R.9040 - Regulate the Price of All Drugs Act
AI-Powered Summary
HOUSE-BILL 9040 aims to establish fair pricing for prescription drugs to enhance access for individuals, particularly those deemed fair price eligible, defined as individuals located in the U.S. at the time of receiving the drug. The legislation addresses major themes of healthcare affordability and regulatory oversight, creating a Prescription Drug Price Regulatory Commission tasked with recommending fair prices and imposing penalties on manufacturers for noncompliance. Key provisions include the establishment of this commission, significant penalties for manufacturers who do not adhere to pricing regulations, and the ability for the Secretary of Health and Human Services to authorize temporary waivers for prices exceeding the fair price. Implementation may raise constitutional concerns regarding due process and equal protection, as well as potential regulatory overreach and conflicts between state and federal authority. The bill's impact could significantly affect individual access to medications, the availability of drugs, and the dynamics of the pharmaceutical market.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill has significant implications for individual rights, particularly in enhancing access to healthcare through regulated drug pricing. It supports the principle of equal protection by potentially lowering costs for vulnerable populations, including low-income individuals and seniors.
Key Individual Rights
- Right to healthcare access
- Equal protection under the law
- Due process rights of pharmaceutical companies
Constitutional Provisions
- Equal Protection Clause (14th Amendment)
- Due Process Clause (5th and 14th Amendments)
- Commerce Clause (Article I, Section 8)
Potential Constitutional Challenges
Pharmaceutical companies may challenge the bill on the grounds that it infringes on their economic rights and property interests, potentially invoking the Takings Clause. Additionally, concerns about stifling innovation in drug development could lead to legal scrutiny.
Summary
HOUSE-BILL 9040 seeks to regulate prescription drug prices, which could significantly improve access to medications for various demographic groups. While it supports individual rights related to healthcare access, it also raises important questions about the balance between regulation and the economic rights of pharmaceutical companies. The bill's implementation will be crucial in determining its overall impact on individual rights and constitutional principles.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention H.R. 9040 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreeTimeline
May 26, 2026
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat